电化学疗法治疗皮肤恶性肿瘤:泛欧数据库987例患者2482个病灶的累积结果与亚组分析
总体缓解率85%(完全缓解70%),不同组织学类型间缓解率存在显著差异(p<0.0001),且与病灶大小相关(以直径3cm二分,p<0.0001)。
要点
- ECT总体缓解率85%,完全缓解率70%,适用于多种皮肤肿瘤组织学类型。
- 不同组织学类型缓解率差异显著(p<0.0001),卡波西肉瘤最高(OR 98%),乳腺癌转移最低(OR 77%)。
- 病灶直径≤3cm时线性阵列电极优于六边形电极(80% vs 74%,p<0.003);>2cm时静脉给药优于瘤内给药(p<0.05)。
核心结论
- 累积数据支持电化学疗法在多种皮肤肿瘤组织学类型中均有效。
- 对2482个病灶的亚组分析为未来治疗选择提供了信息。
研究设计与样本
- 纳入987例患者共2482个肿瘤病灶。
- 分析缓解率与主要诊断、肿瘤大小、电极类型、博来霉素给药途径、电参数及既往照射的关系。
主要发现
- 总体缓解率85%,其中完全缓解70%、部分缓解15%、疾病稳定11%、疾病进展2%。
- 恶性黑色素瘤转移OR 82%、CR 64%;基底细胞癌OR 96%、CR 85%;乳腺癌转移OR 77%、CR 62%;鳞状细胞癌OR 80%、CR 63%;卡波西肉瘤OR 98%、CR 91%。
- 不同组织学类型间差异显著(p<0.0001),且与病灶大小相关(以直径3cm二分,p<0.0001)。
- 病灶≤3cm时线性阵列电极肿瘤控制优于六边形电极(80% vs 74%,p<0.003)。
- 病灶>2cm时静脉给药优于瘤内给药(p<0.05);既往照射区域瘤内给药缓解率选择性降低。
关键数值与推荐
- 总体缓解率85%(CR 70%、PR 15%、SD 11%、PD 2%)。
- 恶性黑色素瘤转移OR 82%、CR 64%;基底细胞癌OR 96%、CR 85%;乳腺癌转移OR 77%、CR 62%;鳞状细胞癌OR 80%、CR 63%;卡波西肉瘤OR 98%、CR 91%。
- 组织学类型间差异p<0.0001;病灶大小(以3cm二分)差异p<0.0001。
- ≤3cm病灶线性阵列电极vs六边形电极肿瘤控制80% vs 74%,p<0.003。
- >2cm病灶静脉给药优于瘤内给药,p<0.05。
临床怎么用
- ECT可用于原发性及继发性皮肤肿瘤,组织学类型和病灶大小影响缓解率。
- 对≤3cm病灶可优先考虑线性阵列电极以改善肿瘤控制。
- 对>2cm病灶静脉给予博来霉素可能优于瘤内给药。
- 既往照射区域行瘤内给药时需注意缓解率可能降低。
局限性
- 记录电流随组织学类型和大小变化,但未影响缓解率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Electrochemotherapy (ECT) is a treatment for both primary and secondary cutaneous tumours. The international Network for sharing practices on ECT group investigates treatment outcomes after ECT using a common database with defined parameters. METHODS: Twenty-eight centres across Europe prospectively uploaded data over an 11-year period. Response rates were investigated in relation to primary diagnosis, tumour size, choice of electrode type, route of bleomycin administration, electrical parameters recorded and previous irradiation in the treated field. RESULTS: Nine hundred eighty-seven patients, with 2482 tumour lesions were included in analysis. The overall response (OR) rate was 85% (complete response [CR]: 70%, partial response rate: 15%, stable disease: 11%, and progressive disease: 2%). For different histologies, OR and CR rates for metastases of malignant melanoma were 82% and 64%, basal cell carcinoma were 96% and 85%, breast cancer metastases were 77% and 62%, squamous cell carcinoma were 80% and 63% as well as Kaposi's sarcoma were 98% and 91%, respectively. Variance was demonstrated across histotypes (p < 0.0001) and in accordance with size of lesion treated (dichotomised at diameter of 3 cm (p < 0.0001). Hexagonal electrodes were generally used for larger tumours, but for tumours up to 3 cm, linear array electrodes provided better tumour control than hexagonal electrodes (80%:74%, p < 0.003). For tumours more than 2 cm, intravenous administration was superior to intratumoural (IT) administration (p < 0.05). Current recorded varied across tumour histologies and size but did not influence response rate. In previously irradiated areas, responses were selectively lower for IT administration. CONCLUSIONS: These cumulative data endorse efficiency of ECT across a broad range of histotypes. Analysis of 2482 lesions details subgroup analysis on treatment response informing future treatment choices.
引用
- Clover AJP, de Terlizzi F, Bertino G, et al. Electrochemotherapy in the treatment of cutaneous malignancy: Outcomes and subgroup analysis from the cumulative results from the pan-European International Network for Sharing Practice in Electrochemotherapy database for 2482 lesions in 987 patients (2008-2019). Eur J Cancer. 2020. PMID: 32836172. doi:10.1016/j.ejca.2020.06.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。